



JRW

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Binie V. Lipps

Frederick W. Lipps

Serial No.: 10/716,981

§ ATTY DCKT NO: FWLPAT013US

§

§

§

§ Art Unit: 1647

§

§

§ Examiner:

§

§

For:

**SYNTHETIC PEPTIDE FOR
NEUROLOGICAL DISORDERS**

Commissioner for Patents

PO Box 1450

Alexandria, VA 22313-1450

§

§

§

**INFORMATION DISCLOSURE STATEMENT (IDS) TRANSMITTAL
LETTER/PETITION FOR CONSIDERATION UNDER 37 CFR §1.97**

I. Enclosed is a Form PTO/SB/08B and copies of the cited items.

II. The Examiner is requested to consider each cited item because:

A. said IDS was filed **BEFORE EXAMINATION:** before the date of the first Office Action on the merits.

III. The cited items were identified in "Partial" and "Supplementary Partial" European Search Reports in a foreign counterpart application and cited as X items against certain claims. The reports were issued December 6, 2004, within three months of this transmittal.

Respectfully submitted:



John R. Casperson

Reg. No. 28,198

Please mail correspondence to:

John R. Casperson
PO Box 2174
Friendswood, Texas 77549

Tel. No. 281-482-2961

I hereby certify that this correspondence and all documents referred to herein is being deposited with the United States Postal Service as first class mail in an envelope addressed to the above addressee on

11 January 2005

 1/11/05
by John R. Casperson, Reg. No. 28,198 (date)

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

1

of

1

<i>Complete if Known</i>	
Application Number	10/716,981
Filing Date	November 19, 2003
First Named Inventor	Lipps et al
Art Unit	1647
Examiner Name	
Attorney Docket Number FWLPAT013US	

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		BEGLOVA et al : "Solution structure...of a bioactive peptide..." J of Biol. Chem., vol 273, no. 37., 11 Sept 1998 pp 23652-658	
		LONGO et al: "Synthetic NGF Peptide...." J of Neurosci Res, Wiley Liss, vol 48, 1 April 1997, pp1-17	
		ESTENNE-BOUHTOU et al: "Design, synthesis,...of NGF Mimetics" Int. J of Peptide and Protein Res., Munksgaard, Copenhagen, DK vol 48, no: 4, 1 Oct 1996, pp 337-346	

Examiner Signature	Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.